The FDA has licensed the emergency use of PAXLOVID for the therapy of mild-to-moderate COVID-19 in adults and youth [12 years of age and older weighing at least 88 kilos (40 kg)] with a wonderful take a look at for the virus that reasons COVID-19, and who are at excessive chance for development to extreme COVID-19, consisting of hospitalization or death, beneath an EUA.
If you take a look at nice for COVID‑19, discuss to your healthcare company as quickly as possible. Your healthcare company can inform you about your cure preferences and if PAXLOVID is terrific for you.
It, also known as nirmatrelvir and ritonavir, is an antiviral medication developed by Pfizer for the treatment of COVID-19. As of my last update in January 2022, Paxlovid had shown promising results in reducing the risk of severe illness and hospitalization in people infected with the SARS-CoV-2 virus. Clinical trials demonstrated its effectiveness in reducing the risk of hospitalization and death by about 89% in high-risk individuals when taken within three days of symptom onset.
However, the effectiveness of treatments can vary based on various factors, including the prevalence of different viral strains and the timing of treatment initiation.